イリノイ州における慢性リンパ性白血病の臨床試験
イリノイ州内の拠点で、慢性リンパ性白血病に関する17件の研究が参加者を募集しています。
イリノイ州内の都市
- Chicago14件の研究
- Evanston4件の研究
- Springfield4件の研究
- Waukegan4件の研究
- Danville3件の研究
- Champaign3件の研究
- Decatur3件の研究
- Charleston3件の研究
公式研究テキスト（英語）
Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
- Illinois CancerCare-Bloomington, Bloomington
- Illinois CancerCare-Canton, Canton
- Illinois CancerCare-Carthage, Carthage
- 他27件
被験者募集中第3相
65歳以上 · 全性別 · 2026/10/02更新 · NCT07321652Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- OSF Saint Anthony's Health Center, Alton
- Rush-Copley Medical Center, Aurora
- Advocate Outpatient Center - Aurora, Aurora
- 他54件
被験者募集中観察研究健康なボランティア歓迎
40歳〜75歳 · 全性別 · 2026/10/02更新 · NCT05334069Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
- Rush-Copley Medical Center, Aurora
- Northwestern University, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
- 他28件
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/30更新 · NCT04269902A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
- Northwestern University, Chicago
- Illinois Cancer Specialists (Niles) Usor, Niles
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/28更新 · NCT06943872A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
- Northwestern University, Chicago
- Midwestern Regional Medical Center, Zion
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/28更新 · NCT07277231A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- University of Chicago Medical Center, Chicago
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/28更新 · NCT06973187Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
- City of Hope - Chicago, Zion
被験者募集中第1/2相
12歳以上 · 全性別 · 2026/09/03更新 · NCT04588922A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies
- The David and Etta Jonas Center for Cellular Therapy, Chicago
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/17更新 · NCT06528301ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL
- Orchard Healthcare Research, Skokie
被験者募集中第3相
18歳以上 · 全性別 · 2026/08/11更新 · NCT07342478A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
- Northwestern University, Chicago
被験者募集中第1相
18歳以上 · 全性別 · 2026/07/02更新 · NCT05131022Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
- University of Chicago, Chicago
被験者募集中第1相
13歳以上 · 全性別 · 2026/05/05更新 · NCT04771572The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
- University of Illinois at Chicago Cancer Center, Chicago
被験者募集中第1/2相
12歳〜95歳 · 全性別 · 2026/04/15更新 · NCT04329728A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
- Springfield Clinic - First /ID# 270145, Springfield
被験者募集中第3相
18歳以上 · 全性別 · 2026/04/09更新 · NCT06428019A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
- The University of Chicago Medical Center, Chicago
被験者募集中第1相
18歳以上 · 全性別 · 2026/03/20更新 · NCT04830137A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
- Northwestern University, Chicago
被験者募集中第4相
18歳以上 · 全性別 · 2026/03/02更新 · NCT06876662A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
- Northwestern University, Chicago
被験者募集中第4相
18歳以上 · 全性別 · 2026/03/02更新 · NCT06876649AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
- Northwestern Memorial Hospital, Chicago
被験者募集中第1相
18歳以上 · 全性別 · 2025/12/10更新 · NCT05602363ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。